Patents by Inventor Han, Chun OU

Han, Chun OU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Controlled drug release liposome compositions and methods thereof
    Patent number: 11147881
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Grant
    Filed: January 7, 2019
    Date of Patent: October 19, 2021
    Assignees: Taiwan Liposome Company, Ltd., TLC Biopharmaceuticals, Inc.
    Inventors: Pei Kan, Yun-Long Tseng, Han-Chun Ou, Chun-yen Lai
  • CONTROLLED DRUG RELEASE LIPOSOME COMPOSITIONS AND METHODS THEREOF
    Publication number: 20190216932
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Application
    Filed: January 7, 2019
    Publication date: July 18, 2019
    Applicants: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Pei KAN, Yun-Long TSENG, Han-Chun OU, Chun-yen LAI
  • Controlled drug release liposome compositions and methods thereof
    Patent number: 10220095
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Grant
    Filed: May 31, 2017
    Date of Patent: March 5, 2019
    Assignees: TAIWAN LIPOSOME COMPANY, LTD, TLC BIOPHARMACEUTICALS, INC
    Inventors: Pei Kan, Yun-Long Tseng, Han-Chun Ou, Chun-yen Lai
  • CONTROLLED DRUG RELEASE LIPOSOME COMPOSITIONS AND METHODS THEREOF
    Publication number: 20170266295
    Abstract: The present invention relates to pharmaceutical compositions comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent or a derivative or pharmaceutically acceptable salt thereof. The present invention also relates to methods of inhibiting cancer cell growth while reducing toxicity, comprising administering the pharmaceutical composition described herein.
    Type: Application
    Filed: May 31, 2017
    Publication date: September 21, 2017
    Applicants: TAIWAN LIPOSOME COMPANY, LTD., TLC BIOPHARMACEUTICALS, INC.
    Inventors: Pei KAN, Yun-Long TSENG, Han-Chun OU, Chun-yen LAI
  • Controlled drug release liposome composition
    Patent number: 9700511
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent. The present invention also relates to methods of inhibiting cancer cell growth, comprising administering the pharmaceutical composition described herein.
    Type: Grant
    Filed: March 15, 2014
    Date of Patent: July 11, 2017
    Assignees: TLC Biopharmaceuticals, Inc., Taiwan Liposome Company, Ltd.
    Inventors: Pei Kan, Yun-Long Tseng, Han Chun Ou
  • CONTROLLED DRUG RELEASE LIPOSOME COMPOSITION
    Publication number: 20160030340
    Abstract: The present invention relates to a pharmaceutical composition comprising at least one liposome, at least one polyvalent counterion donor or a pharmaceutically acceptable salt thereof, at least one monovalent counterion donor or a pharmaceutically acceptable salt thereof, and an amphipathic therapeutic agent. The present invention also relates to methods of inhibiting cancer cell growth, comprising administering the pharmaceutical composition described herein.
    Type: Application
    Filed: March 15, 2014
    Publication date: February 4, 2016
    Inventors: Pei KAN, Yun-Long TSENG, Han, Chun OU